Processa Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 5, 2020

SEC Form 4/A — Form 4/A

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2020-10-01

Reporting Person: Stanker James H (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-01	Common Stock	P	6000	$4.00	Acquired	47248	Direct

Footnotes

F1: This amended Form 4 is being filed to correct the purchase price for the reported transaction.